Abstract: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease, often involving multiple systems, accompanied by abnormal glucose metabolism and lipid metabolism. Hydroxychloroquine has been found to have a protective effect on blood glucose and blood lipid in SLE patients while treating the disease which as one of the basic drugs for systemic lupus erythematosus. The update of the effect of hydroxychloroquine on dyslipidemia and blood glucose in systemic lupus erythematosus patients is reviewed in this article.

Key words: systemic lupus erythematosus, hydroxychloroquine, dyslipidemia, blood glucose